Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV – Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation,...

Atlantic Healthcare Reports Results from Phase 1 Trial of Tablet for Crohns CAMBRIDGE, UK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Oral Alicaforsen Appears Safe and Well-Tolerated via NEWMEDIAWIRE – Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist...